iBio reports single dose of IBIO-610 cut active Activin E ~98% through eight weeks in obese NHPs

iBio achieved near-complete Activin E inhibition (98% at week 4; 97% at week 8) after a single dose of IBIO-610 in obese NHPs.Key Highlights:Original SEC Filing: iBio, Inc. [ IBIO ] - 8-K - Jul. 01, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important informa…

iBio achieved near-complete Activin E inhibition (98% at week 4; 97% at week 8) after a single dose of IBIO-610 in obese NHPs.

Key Highlights:

Single-dose IBIO-610 reduced active Activin E by 98% at week 4 and 97% at week 8 versus baseline.
Active Activin E levels were suppressed to below assay limits at weeks 4 and 8 in all treated NHPs.
Data support potential for infrequent dosing and a long-acting antibody approach targeting Activin E pathway.
When combined with semaglutide, IBIO-610 increased visceral and total fat loss while cutting lean mass loss by 73% vs semaglutide alone.
Full dataset to be presented at the EASD Annual Meeting in Milan, Sept 28–Oct 2 (presentation Oct 1).

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.